{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:09:29Z","timestamp":1740136169404,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T00:00:00Z","timestamp":1512950400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["26461183","26462000","16K09598"],"award-info":[{"award-number":["26461183","26462000","16K09598"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12935-017-0493-8","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T13:31:23Z","timestamp":1512999083000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells"],"prefix":"10.1186","volume":"17","author":[{"given":"Yiyang","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengmeng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Shingyoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Hanazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,11]]},"reference":[{"key":"493_CR1","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of PEM in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"493_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s40064-016-1893-2","volume":"5","author":"Y Tada","year":"2016","unstructured":"Tada Y, Hiroshima K, Shimada H, Shingyoji M, Suzuki T, Umezawa H, et al. An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol. Springerplus. 2016;5:195.","journal-title":"Springerplus"},{"key":"493_CR3","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2147\/DDDT.S106412","volume":"10","author":"H Zhu","year":"2016","unstructured":"Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Dev Ther. 2016;10:1885\u20139.","journal-title":"Drug Des Dev Ther"},{"key":"493_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10555-007-9049-z","volume":"26","author":"YG Assaraf","year":"2007","unstructured":"Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev. 2007;26:153\u201381.","journal-title":"Cancer Metastasis Rev"},{"key":"493_CR5","first-page":"2677","volume":"6","author":"HL McLeod","year":"2000","unstructured":"McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW, et al. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res. 2000;6:2677\u201384.","journal-title":"Clin Cancer Res"},{"key":"493_CR6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3892\/ol.2013.1688","volume":"7","author":"M Yang","year":"2014","unstructured":"Yang M, Fan WF, Pu XL, Liu FY, Meng LJ, Wang J. Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma. Oncol Lett. 2014;7:227\u201332.","journal-title":"Oncol Lett"},{"key":"493_CR7","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/1535-7163.MCT-13-0172","volume":"12","author":"LD Weeks","year":"2013","unstructured":"Weeks LD, Fu P, Gerson SL. Uracil-DNA glycosylase expression determines human lung cancer cell sensitivity to pemetrexed. Mol Cancer Ther. 2013;12:2248\u201360.","journal-title":"Mol Cancer Ther"},{"key":"493_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.yexcr.2014.02.002","volume":"322","author":"CL Tung","year":"2014","unstructured":"Tung CL, Chiu HC, Jian YJ, Jian YT, Chen CY, Syu JJ, et al. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells. Exp Cell Res. 2014;322:345\u201354.","journal-title":"Exp Cell Res"},{"key":"493_CR9","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.3892\/or.2014.3027","volume":"31","author":"Z Yu","year":"2014","unstructured":"Yu Z, Li XM, Liu SH, Liu B, Gao CH, Hou X. Downregulation of both EGFR and ErbB3 improves the cellular response to pemetrexed in an established pemetrexed-resistant lung adenocarcinoma A549 cell line. Oncol Rep. 2014;31:1818\u201324.","journal-title":"Oncol Rep"},{"key":"493_CR10","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1158\/0008-5472.CAN-08-4979","volume":"69","author":"AC Racanelli","year":"2009","unstructured":"Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: PEM causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res. 2009;69:5467\u201374.","journal-title":"Cancer Res"},{"key":"493_CR11","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0014-5793(95)01313-X","volume":"377","author":"SP Davies","year":"1995","unstructured":"Davies SP, Helps NR, Cohen PT, Hardie DG. 5\u2032-AMP inhibits de-phosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC. FEBS Lett. 1995;377:421\u20135.","journal-title":"FEBS Lett"},{"key":"493_CR12","first-page":"33","volume":"28","author":"M Kitazono-Saitoh","year":"2012","unstructured":"Kitazono-Saitoh M, Takiguchi Y, Kitazono S, Ashinuma H, Kitamura A, Tada Y, et al. Interaction and cross-resistance of cisplatin and PEM in malignant pleural mesothelioma cell lines. Oncol Rep. 2012;28:33\u201340.","journal-title":"Oncol Rep"},{"key":"493_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1349-7006.2006.00163.x","volume":"97","author":"E Nakataki","year":"2006","unstructured":"Nakataki E, Yano S, Matsumori Y, Goto H, Kakiuchi S, Muguruma H, et al. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci. 2006;97:183\u201391.","journal-title":"Cancer Sci"},{"key":"493_CR14","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4161\/cc.27546","volume":"13","author":"D Di Marzo","year":"2014","unstructured":"Di Marzo D, Forte IM, Indovina P, Di Gennaro E, Rizzo V, Giorgi F, et al. Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell Cycle. 2014;13:652\u201365.","journal-title":"Cell Cycle"},{"key":"493_CR15","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/onc.2012.146","volume":"32","author":"M Cort\u00e9s-Sempere","year":"2013","unstructured":"Cort\u00e9s-Sempere M, de Miguel MP, Pern\u00eda O, Rodriguez C, de Castro Carpe\u00f1o J, Nistal M, et al. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR\/Akt pathway in non-small cell lung cancer. Oncogene. 2013;32:1274\u201383.","journal-title":"Oncogene"},{"key":"493_CR16","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1158\/1535-7163.MCT-06-0305","volume":"5","author":"E Barbieri","year":"2006","unstructured":"Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S, et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther. 2006;5:2358\u201365.","journal-title":"Mol Cancer Ther"},{"key":"493_CR17","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.humpath.2008.04.009","volume":"39","author":"N Ishiguro","year":"2008","unstructured":"Ishiguro N, Motoi T, Araki N, Ito H, Moriyama M, Yoshida H. Expression of cardiac ankyrin repeat protein, CARP, in malignant tumors: diagnostic use of CARP protein immunostaining in rhabdomyosarcoma. Hum Pathol. 2008;39:1673\u20139.","journal-title":"Hum Pathol"},{"key":"493_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1631\/jzus.B1500247","volume":"17","author":"N Zhang","year":"2016","unstructured":"Zhang N, Xie XJ, Wang JA. Multifunctional protein: cardiac ankyrin repeat protein. J Zhejiang Univ Sci B. 2016;17:333\u201341.","journal-title":"J Zhejiang Univ Sci B"},{"key":"493_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.jidsymp.5650014","volume":"11","author":"SE Samaras","year":"2006","unstructured":"Samaras SE, Shi Y, Davidson JM. CARP: fishing for novel mechanisms of neovascularization. J Investig Dermatol Symp Proc. 2006;11:124\u201331.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"493_CR20","doi-asserted-by":"publisher","first-page":"6924","DOI":"10.1158\/1078-0432.CCR-07-5189","volume":"14","author":"LL Scurr","year":"2008","unstructured":"Scurr LL, Guminski AD, Chiew YE, Balleine RL, Sharma R, Lei Y, et al. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer. Clin Cancer Res. 2008;14:6924\u201332.","journal-title":"Clin Cancer Res"},{"key":"493_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/onc.2013.566","volume":"34","author":"Y Lei","year":"2015","unstructured":"Lei Y, Henderson BR, Emmanuel C, Harnett PR, deFazio A. Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis. Oncogene. 2015;34:485\u201395.","journal-title":"Oncogene"},{"key":"493_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.abb.2010.06.029","volume":"502","author":"S Kojic","year":"2010","unstructured":"Kojic S, Nestorovic A, Rakicevic L, Belgrano A, Stankovic M, Divac A, et al. A novel role for cardiac ankyrin repeat protein Ankrd1\/CARP as a co-activator of the p53 tumor suppressor protein. Arch Biochem Biophys. 2010;502:60\u20137.","journal-title":"Arch Biochem Biophys"},{"key":"493_CR23","doi-asserted-by":"publisher","first-page":"23122","DOI":"10.1074\/jbc.M501095200","volume":"280","author":"XJ Han","year":"2005","unstructured":"Han XJ, Chae JK, Lee MJ, You KR, Lee BH, Kim DG. Involvement of GADD153 and cardiac ankyrin repeat protein in hypoxia-induced apoptosis of H9c2 cells. J Biol Chem. 2005;280:23122\u20139.","journal-title":"J Biol Chem"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-017-0493-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12935-017-0493-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-017-0493-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T07:59:30Z","timestamp":1589529570000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-017-0493-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["493"],"URL":"https:\/\/doi.org\/10.1186\/s12935-017-0493-8","relation":{},"ISSN":["1475-2867"],"issn-type":[{"type":"electronic","value":"1475-2867"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"14 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"120"}}